Tempus AI announced the launch of Paige Predict, a suite of AI‑powered digital pathology applications that analyze hematoxylin and eosin (H&E) whole‑slide images to predict the likelihood of 123 clinically actionable biomarkers across 16 cancer types, including non‑small cell lung cancer, prostate, breast, pancreatic, and colorectal cancers.
Paige Predict is built on a foundation model trained on a multimodal cohort of more than 200,000 de‑identified patient cases. The model can infer biomarker status even when tissue samples are insufficient for full molecular profiling, directly addressing the “quantity not sufficient” bottleneck that often delays treatment decisions.
The launch expands Tempus’s precision‑medicine platform beyond genomics and data licensing. It follows the company’s 2025 acquisition of Paige for $81.25 million in stock, which provided the core imaging expertise and data needed to develop the new tool. By integrating pathology imaging with its existing multimodal data ecosystem, Tempus creates a new revenue stream and strengthens its competitive moat.
Financially, Tempus reported a gross profit margin of 61.73 percent and a record total contract value exceeding $1.1 billion as of December 31, 2025. Preliminary application revenue for 2025 was approximately $316 million, a 31 percent year‑over‑year increase, while the insights (data licensing) segment grew 38 percent. The new AI pathology offering aligns with the company’s broader strategy to monetize its AI platform and accelerate diagnostic workflows.
The AI pathology market is expanding rapidly, and Paige Predict positions Tempus against competitors such as PathAI and other emerging digital pathology vendors. By reducing delays caused by limited tissue, the tool has the potential to improve patient outcomes and accelerate the adoption of precision oncology.
Ezra Cohen, Chief Medical Officer of Oncology at Tempus, emphasized the tool’s value: “Tissue can be scarce, but insights don’t have to be.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.